quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:46:55·41d
ANALYSTRating
Apellis Pharmaceuticals Inc. logo

Roth Capital initiated coverage on Apellis Pharmaceuticals with a new price target

APLS· Apellis Pharmaceuticals Inc.
Health Care
Original source

Companies

  • APLS
    Apellis Pharmaceuticals Inc.
    Health Care

Recent analyst ratings

  • Mar 13UpdateRoth Capital$31.00
  • Jan 28UpdateBarclays$24.00
  • Jan 21UpdateBofA Securities$28.00
  • Nov 6UpdateWolfe Research-
  • Oct 15UpdateWells Fargo$32.00
  • Sep 26UpdateGoldman$18.00

Related

  • INSIDER3d
    SEC Form 4 filed by Sullivan Timothy Eugene
  • SEC9d
    SEC Form SC 14D9 filed by Apellis Pharmaceuticals Inc.
  • SEC9d
    SEC Form SC TO-T filed by Apellis Pharmaceuticals Inc.
  • INSIDER15d
    SEC Form 4 filed by O'Brien Stephanie Monaghan
  • SEC16d
    SEC Form SC TO-C filed by Apellis Pharmaceuticals Inc.
  • SEC16d
    Amendment: SEC Form SCHEDULE 13G/A filed by Apellis Pharmaceuticals Inc.
  • INSIDER17d
    SEC Form 3 filed by new insider Biogen Inc.
  • SEC17d
    SEC Form SCHEDULE 13D filed by Apellis Pharmaceuticals Inc.
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022